Tolerability and Efficacy of Adjuvant T-DM1 in Patients with HER2 Positive Breast Cancer After Incomplete Pathological Response to Neoadjuvant Chemotherapy Including Anti-HER2 Agents.
NCT06272799
·
clinicaltrials.gov ↗
RECRUITING
Status
160
Enrollment
OTHER
Sponsor class
Conditions
Breast Cancer
Interventions
DRUG:
T-DM1 adjuvant
Sponsor
Regina Elena Cancer Institute